Neurogene (NGNE) Current Assets (2013 - 2026)

Neurogene (NGNE) has 14 years of Current Assets data on file, last reported at $246.7 million in Q1 2026.

• Quarterly Current Assets fell 16.75% year-over-year to $246.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $246.7 million (down 16.75% YoY) and the FY2025 annual result came in at $271.8 million, down 13.98% from the prior year.
• Current Assets declined to $246.7 million in Q1 2026, from $271.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $315.9 million in Q4 2024 to a low of $79.9 million in Q3 2023.
• A 5-year average of $179.4 million and a median of $159.1 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets sank 41.16% — and 2023, when it jumped 136.49%.
• Tracing NGNE's Current Assets over 5 years: stood at $84.7 million in 2022, then jumped by 136.49% to $200.3 million in 2023, then soared by 57.69% to $315.9 million in 2024, then fell by 13.98% to $271.8 million in 2025, then dropped by 9.21% to $246.7 million in 2026.
• The last three Current Assets figures came in at $246.7 million (Q1 2026), $271.8 million (Q4 2025), and $270.5 million (Q3 2025), per Business Quant data.